Proteomic Prediction of Clinical Benefit in HNSCC
OBJECTIVES:
- To identify head and neck squamous cell cancer patients who will benefit from treatment
with the EGFR inhibitors (i.e., erlotinib hydrochloride, gefitinib, and cetuximab) and
VEGF inhibitor (i.e., bevacizumab), based on predictive proteomic profiles in patient
blood samples.
OUTLINE: This is a multicenter study.
Blood samples are analyzed for proteomic profile to determine good and bad prognoses in
patients treated with or without EGFR inhibitors and/or a VEGF inhibitor.
Observational
Observational Model: Case-Only, Time Perspective: Retrospective
Identification of patients who will benefit from treatment with EGFR and/or VEGF inhibitors based on serum proteomic profiles
upon analysis of each patient tissue collection
No
Barbara Murphy, MD
Study Chair
Vanderbilt-Ingram Cancer Center
United States: Federal Government
VICC HN 0744
NCT00896675
June 2007
December 2009
Name | Location |
---|---|
Vanderbilt-Ingram Cancer Center | Nashville, Tennessee 37232-6838 |
Vanderbilt-Ingram Cancer Center - Cool Springs | Nashville, Tennessee 37064 |
Vanderbilt-Ingram Cancer Center at Franklin | Nashville, Tennessee 37064 |